| Description | Thalidomide-O-C7-acid is a compound created through the synthesis of an E3 ligase ligand-linker conjugate. It consists of a cereblon ligand derived from Thalidomide, combined with a linker that is commonly employed in PROTAC technology. |
| In vitro | PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins[2]. |
| Synonyms | Thalidomide-O-C7-acid |
| molecular weight | 416.43 |
| Molecular formula | C21H24N2O7 |
| CAS | 2169266-70-8 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| References | 1. Sato T, et al. Cereblon-Based Small-Molecule Compounds to Control Neural Stem Cell Proliferation in Regenerative Medicine. Front Cell Dev Biol. 2021;9:629326. Published 2021 Mar 11. 2. Nalawansha DA, et al. PROTACs: An Emerging Therapeutic Modality in Precision Medicine. Cell Chem Biol. 2020;27(8):998-1008. |